Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl)a cet amide]: Analysis of drug adducts by fluorescent antibodies vs bound radioactivity

British Journal of Cancer

Volumn 72, Issue 4, 1995, Pages 869-874

  Koch, C J ^a   Evans, S M ^a   Lord, E M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

2 nitroimidazole; 2 (2 nitro lH imidazol 1 yl) N (2, 2, 3, 3, 3 pentafluoropropyl)acetamide; Bioreductive drugs; Fluorescence immunohistochemistry; Hypoxic cells; Oxygen effect; Oxygen measurement; Radiation response

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; ACETAMIDE DERIVATIVE; ANTIBODY; ETANIDAZOLE; FLUORESCENT DYE; MONOCLONAL ANTIBODY; OXYGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LYSATE; CHINESE HAMSTER; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG UPTAKE; FIBROBLAST; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; GLIOMA CELL; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT;

ANIMAL; ANTINEOPLASTIC AGENTS; CELL LINE; ETANIDAZOLE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HAMSTERS; HYDROCARBONS, FLUORINATED; OXYGEN; RADIATION-SENSITIZING AGENTS; RATS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028839715     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.426     Document Type: Article

References (30)

1. CHAPMAN JD. (1979). Hypoxic sensitizers -implications for radiation therapy. New Engl. J. Med., 301, 1429–1432.
2. CHAPMAN JD, BAER K, AND LEE J. (1983). Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res., 43, 1523–1528.
3. COBB LM, NOLAN J, AND O’NEILL P. (1989). Microscopic distribution of misonidazole in mouse tissues. Br. J. Cancer, 59, 12–16.
4. COBB LM, NOLAN J, AND HACKER T. (1992). Retention of misonidazole in normal and malignant tissues: interplay of hypoxia and reductases. Int. J. Radiat. Oncol. Biol. Phys., 22, 655–659.
5. EVANS SM, AND KOCH CJ. (1994). Characterization of the 9L glioma as a tissue isolated epigastric implant. Radiat. Oncol. Invest, 2, 134–143.
6. EVANS SM, KOCH CJ, JOINER B, JENKINS WT, LAUGHLIN KM, AND LORD EM. (1995). 2-Nitroimidazole binding for identification of hypoxic cell fraction in cells and tissues of epigastric 9L tumours. Br. J. Cancer, 72, 888–895.
7. FRANKO AJ, AND KOCH CJ. (1984). Binding of misonidazole to V79 spheroids and fragments of Dunning rat prostate and human colon carcinoma in vitro: diffusion of oxygen and reactive metabolites. Int. J. Radiat. Oncol. Biol. Phys., 10, 1333–1337.
8. FRANKO AJ, KOCH CJ, GARRECHT BM, SHARPLIN J, AND HOWORKO J. (1987). Oxygen dependence of binding of misonidazole to rodent and human tumours in vitro. Cancer Res., 47, 5367–5376.
9. HODGKISS RJ, JONES G, LONG A, PARRICK J, SMITH KA, AND STRATFORD MRL. (1991). Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br. J. Cancer, 63, 119–125.
10. HOWELL RL, AND KOCH CJ. (1980). The disaggregation, separation and identification of cells from irradiated and unirradiated EMT6 mouse tumors. Int. J. Radiat. Oncol. Biol. Phys., 6, 311–318.
11. JOSEPH P, JAISWAL K, STOBBE C, AND CHAPMAN JD. (1994). The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys., 29, 351–355.
12. KOCH CJ. (1984). A thin-film culturing technique allowing rapid gas-liquid equilibration (6 seconds) with no toxicity to mammalian cells. Radiat. Res., 97, 434–442.
13. KOCH CJ. (1990). The reductive activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems. In Selective Activation of Drugs by Redox Processes, Adams GE, Breccia A, Fielden EM and Wardman P. (eds) pp. 237-247. Plenum Press: New York.
14. 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration. Int. J. Radiat. Oncol. Biol. Phys., 10, 1327–1332.
15. KOCH CJ, STOBBE CC, AND HETTIARATCHI P. (1989). Combined radiation-protective and radiation-sensitizing agents: IV Measurement of intracellular protector concentrations. Int. J. Radiat. Oncol. Biol. Phys., 16, 1025–1027.
16. KOCH CJ, GIANDOMENICO AR, AND LEE IYENGAR CW. (1993). Bioreductive metabolism of AF-2 [2(2-furyl)-3-(5-nitro-2-furyl)-acrylamide] combined with 2-nitroimidazole radiosensitizing agents. Biochem. Pharmacol., 46, 1029–1036.
17. KOCH CJ, EVANS SM, AND LORD EM. (1995). Comment on the hypothesis that hyperthermia facilitates reoxygenation. Int. J. Hyperthermia, 11, 447–450.
18. LORD EM, HARWELL L, AND KOCH CJ. (1993). Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res., 53, 5271–5276.
19. PARLIAMENT MB, CHAPMAN JD, URTASUN RC, MCEWAN AJ, GOLBERG L, MERCER JR, MANNAN RH, AND WIEBE LI. (1992). Non-invasive assessment of human tumour hypoxia with 1-iodoazomycin arabinoside: preliminary report of a clinical study. Br. J. Cancer, 65, 90–95.
20. RALEIGH JA, AND KOCH CJ. (1990). The importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol., 40, 2457–2464.
21. RALEIGH JA, FRANKO AJ, TREIBER EO, LUNT JA, AND ALLEN PS. (1984). Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumours in Balb/c mice: detection by F-19 nuclear magnetic resonance at 2.35 T. Int. J. Radiat. Oncol. Biol. Phys., 10, 1337–1340.
22. RALEIGH JA, MILLER GG, FRANKO AJ, KOCH CJ, FUCIARELLI AF, AND KELLEY DA. (1987). Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br. J. Cancer, 56, 395–400.
23. RASEY JS, GRUNBAUM Z, MAGEE S, NELSON NJ, OLIVE PL, DURAND RE, AND KROHN KA. (1987). Characterization of radiolabelled fluoromisonidazole as a probe for hypoxic cells. Radiat. Res., III, 292–304.
24. SOUTHWICK PL, ERNST LA, TAURIELLO EW, PARKER SR, MUJUMDAR RB, MUJUMBDAR SR, CLEVER HA, AND WAGGONER AS. (1990). Cyanine dye labeling reagents -carboxy-methylindocyanine succinimidyl esters. Cytometry, 11, 418–430.
25. THOMLINSON RH, AND GRAY LH. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer, 9, 539–579.
26. URTASUN RC, KOCH CJ, FRANKO AJ, RALEIGH JA, AND CHAPMAN JD. (1985). A novel technique for measuring human tissue hypoxia at the cellular level. Br. J. Cancer, 54, 453–457.
27. VALNES K, AND BRANDTZAEG P. (1985). Retardation of immunofluorescence fading during microscopy. J. Histochem. Cytochem., 33, 755–761.
28. VARGHESE AJ, GULYAS S, AND MOHINDRA JK. (1976). Hypoxia-dependent reduction of l-(2-nitro-l-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res., 36, 3761–3765.
29. WONG K-H, KOCH CJ, WALLEN CA, AND WHEELER KT. (1991). Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions. Br. J. Cancer, 63, 484–488.
30. WORKMAN P. (1992). Bioreductive mechanisms. (Keynote address) Int. J. Radiat. Oncol. Biol. Phys., 22, 631–637.